• Co-founder and member of the Board of Directors • Established the strategic R&D roadmap for the preclinical and clinical development of Elthera’s anti-L1CAM antibody therapy • Built and managed internal R&D team and led scientific collaborations with academic partners and CROs • Authored variety of grant applications and successfully raised > EUR 3M in non-dilutive funding • Developed IP strategy and authored patent applications • Supported business development by actively pursuing partnership and licensing opportunities with biotech and pharma companies • Participated in selection of contract manufacturing organizations for GMP production of lead antibody product • Provided continuous strategic input and operative support in areas of overall corporate strategy, financial planning, equity funding

• Managed a pharmacological/bioanalytical laboratory with 12 scientists and associates • Designed bioanalytical strategy and developed standardized bioanalytical assays (PK, PD, ADA) for preclinical and clinical studies of antibody fragments for ophthalmic indications • Managed in house qualification/pre-validation of bioanalytical assays, their transfer to CROs, and their validation and implementation under GLP • Managed development of biochemical, cellular and immunological assays for the screening and optimization of antibody candidates • Elaborated and implemented discovery and lead optimization strategies in collaboration with other line functions • Acted as Project leader and/or PK/PD line function representative of local and global cross-functional matrix teams within Novartis • Managed external scientific collaborations with academic partners and CROs

• Responsible for development and qualification of immunoassays for measurement of antibody responses and biomarkers in clinical samples • Supervised and coached a research group consisting of three scientific associates

• Acted as project leader and leader of cross-functional vaccine development programs in the area of infectious, autoimmune, metabolic and bone-degenerative diseases • Managed a research group consisting of three to four scientific associates • Elaborated and implemented strategies for vaccine design and preclinical efficacy and safety testing • Developed biological and immunological assays for the analysis of immune responses to vaccine candidates • Participated in preparation of IND-filings, authored regulatory documents (pre-IND briefing books, IBs, CTAs) • Managed animal experimentation licenses with veterinary authorities • Managed external scientific collaborations with CROs, companies and universities • Published research results in peer-reviewed journals and authored several patent applications